Filing Details
- Accession Number:
- 0001209191-22-016537
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-04 21:07:02
- Reporting Period:
- 2022-01-01
- Accepted Time:
- 2022-03-04 21:07:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1652130 | Intellia Therapeutics Inc. | NTLA | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1563584 | M John Leonard | C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-01-01 | 7,848 | $0.00 | 727,153 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-01-01 | 2,493 | $112.26 | 724,660 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2022-03-01 | 40,990 | $0.00 | 765,650 | No | 4 | A | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | A | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Disposition | 2022-01-01 | 7,848 | $0.00 | 7,848 | $0.00 |
Common Stock | Stock Option (right to buy) | Acquisiton | 2022-03-01 | 59,941 | $0.00 | 59,941 | $79.85 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
23,546 | 2022-01-01 | 2031-03-02 | No | 4 | M | Direct |
59,941 | 2032-02-28 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 58,415 | Indirect | By Trust |
Footnotes
- Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
- Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- Shares held by the John M. Leonard 2015 Irrevocable Trust.
- On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
- This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.